Louisiana State Employees Retirement System Buys New Shares in Xencor, Inc. (NASDAQ:XNCR)

Louisiana State Employees Retirement System bought a new stake in Xencor, Inc. (NASDAQ:XNCRGet Rating) in the 3rd quarter, Holdings Channel reports. The firm bought 28,500 shares of the biopharmaceutical company’s stock, valued at approximately $740,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. US Bancorp DE grew its stake in shares of Xencor by 324.9% in the second quarter. US Bancorp DE now owns 939 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 718 shares in the last quarter. Nisa Investment Advisors LLC bought a new position in Xencor during the second quarter worth $27,000. Lazard Asset Management LLC boosted its position in Xencor by 203.0% during the first quarter. Lazard Asset Management LLC now owns 4,485 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 3,005 shares during the period. KBC Group NV boosted its position in Xencor by 71.1% during the second quarter. KBC Group NV now owns 5,070 shares of the biopharmaceutical company’s stock worth $139,000 after purchasing an additional 2,106 shares during the period. Finally, Virtus ETF Advisers LLC boosted its position in Xencor by 12.9% during the second quarter. Virtus ETF Advisers LLC now owns 5,185 shares of the biopharmaceutical company’s stock worth $142,000 after purchasing an additional 593 shares during the period. 98.99% of the stock is owned by institutional investors.

Xencor Stock Up 3.2 %

XNCR stock opened at $27.00 on Friday. The company has a market cap of $1.62 billion, a PE ratio of 56.25 and a beta of 0.65. The business has a 50-day simple moving average of $27.98 and a 200 day simple moving average of $28.10. Xencor, Inc. has a 52 week low of $19.35 and a 52 week high of $40.05.

Xencor (NASDAQ:XNCRGet Rating) last issued its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.22. The firm had revenue of $27.30 million during the quarter, compared to the consensus estimate of $15.33 million. Xencor had a return on equity of 4.04% and a net margin of 10.07%. On average, analysts anticipate that Xencor, Inc. will post -1.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. StockNews.com raised shares of Xencor from a “sell” rating to a “hold” rating in a research report on Monday, November 14th. Cowen assumed coverage on shares of Xencor in a research report on Tuesday, December 6th. They set an “outperform” rating for the company. JPMorgan Chase & Co. assumed coverage on shares of Xencor in a research report on Wednesday, September 21st. They set an “overweight” rating and a $37.00 price objective for the company. Royal Bank of Canada reduced their price objective on shares of Xencor from $40.00 to $36.00 and set an “outperform” rating for the company in a research report on Tuesday, November 8th. Finally, Cowen assumed coverage on Xencor in a report on Tuesday, December 6th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $48.89.

Insider Activity at Xencor

In other news, CMO Allen Yang sold 3,737 shares of the company’s stock in a transaction that occurred on Monday, December 19th. The stock was sold at an average price of $27.00, for a total transaction of $100,899.00. Following the transaction, the chief marketing officer now directly owns 63,521 shares of the company’s stock, valued at $1,715,067. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.23% of the stock is currently owned by company insiders.

Xencor Company Profile

(Get Rating)

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Recommended Stories

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCRGet Rating).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.